FOLH1 and Familial prostate cancer: Indeed, emerging studies suggest that PSMA-PET detects prostate cancer with superior sensitivity to conventional imaging, as the study by Fendler et al., in which PSMA-PET was positive in 196 of 200 patients with high-risk nmCRPC and detected 55% of M1 disease and 44% of pelvic disease despite negative conventional imaging (42); and the study by Fourquet and colleagues, which used PSMA-PET to restage 30 nmCRPC patients and found at least one malignant focus in 90% of those (43).